DUBLIN, Nov 7 (Reuters) - Ireland's Elan (ELN.I) and U.S. drugmaker Biogen Idec (BIIB.O) have amended the label of their multiple sclerosis drug Tysabri to reflect the increased risk of contracting a potentially deadly brain infection, Elan said in a statement on Saturday.